vs
Side-by-side financial comparison of BingEx Ltd (FLX) and AMICUS THERAPEUTICS, INC. (FOLD). Click either name above to swap in a different company.
AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $143.2M, roughly 1.3× BingEx Ltd). BingEx Ltd runs the higher net margin — 2.2% vs 0.9%, a 1.3% gap on every dollar of revenue.
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
FLX vs FOLD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $143.2M | $185.2M |
| Net Profit | $3.2M | $1.7M |
| Gross Margin | 10.8% | 85.7% |
| Operating Margin | — | 8.6% |
| Net Margin | 2.2% | 0.9% |
| Revenue YoY | — | 23.7% |
| Net Profit YoY | — | -88.5% |
| EPS (diluted) | — | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $143.2M | — | ||
| Q4 25 | — | $185.2M | ||
| Q3 25 | $141.2M | $169.1M | ||
| Q2 25 | $143.0M | $154.7M | ||
| Q1 25 | $141.0M | $125.2M | ||
| Q4 24 | — | $149.7M | ||
| Q3 24 | $164.6M | $141.5M | ||
| Q2 24 | — | $126.7M |
| Q1 26 | $3.2M | — | ||
| Q4 25 | — | $1.7M | ||
| Q3 25 | $6.1M | $17.3M | ||
| Q2 25 | $7.5M | $-24.4M | ||
| Q1 25 | $27.6M | $-21.7M | ||
| Q4 24 | — | $14.7M | ||
| Q3 24 | $3.4M | $-6.7M | ||
| Q2 24 | — | $-15.7M |
| Q1 26 | 10.8% | — | ||
| Q4 25 | — | 85.7% | ||
| Q3 25 | 11.1% | 88.5% | ||
| Q2 25 | 12.0% | 90.2% | ||
| Q1 25 | 10.0% | 90.7% | ||
| Q4 24 | — | 90.1% | ||
| Q3 24 | 11.3% | 90.6% | ||
| Q2 24 | — | 91.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 8.6% | ||
| Q3 25 | 1.4% | 20.3% | ||
| Q2 25 | 1.9% | -6.1% | ||
| Q1 25 | — | -6.3% | ||
| Q4 24 | — | 10.7% | ||
| Q3 24 | 4.0% | 15.3% | ||
| Q2 24 | — | 11.8% |
| Q1 26 | 2.2% | — | ||
| Q4 25 | — | 0.9% | ||
| Q3 25 | 4.4% | 10.2% | ||
| Q2 25 | 5.2% | -15.8% | ||
| Q1 25 | 19.6% | -17.3% | ||
| Q4 24 | — | 9.8% | ||
| Q3 24 | 2.1% | -4.8% | ||
| Q2 24 | — | -12.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | $0.00 | ||
| Q3 25 | — | $0.06 | ||
| Q2 25 | — | $-0.08 | ||
| Q1 25 | — | $-0.07 | ||
| Q4 24 | — | $0.05 | ||
| Q3 24 | — | $-0.02 | ||
| Q2 24 | — | $-0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $561.1M | $293.5M |
| Total DebtLower is stronger | — | $392.7M |
| Stockholders' EquityBook value | — | $274.2M |
| Total Assets | $1.3B | $949.9M |
| Debt / EquityLower = less leverage | — | 1.43× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $561.1M | — | ||
| Q4 25 | — | $293.5M | ||
| Q3 25 | $628.6M | $263.8M | ||
| Q2 25 | $499.4M | $231.0M | ||
| Q1 25 | $592.4M | $250.6M | ||
| Q4 24 | — | $249.9M | ||
| Q3 24 | $517.4M | $249.8M | ||
| Q2 24 | — | $260.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | $392.7M | ||
| Q3 25 | — | $392.0M | ||
| Q2 25 | — | $391.3M | ||
| Q1 25 | — | $390.7M | ||
| Q4 24 | — | $390.1M | ||
| Q3 24 | — | $389.5M | ||
| Q2 24 | — | $388.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $274.2M | ||
| Q3 25 | — | $230.4M | ||
| Q2 25 | — | $204.3M | ||
| Q1 25 | — | $193.6M | ||
| Q4 24 | — | $194.0M | ||
| Q3 24 | — | $178.8M | ||
| Q2 24 | — | $132.5M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | — | $949.9M | ||
| Q3 25 | $1.3B | $868.8M | ||
| Q2 25 | $1.2B | $815.3M | ||
| Q1 25 | $1.2B | $789.8M | ||
| Q4 24 | — | $785.0M | ||
| Q3 24 | $926.8M | $786.6M | ||
| Q2 24 | — | $749.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.02× | ||
| Q4 24 | — | 2.01× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | — | 2.93× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $16.3M |
| Free Cash FlowOCF − Capex | — | $16.0M |
| FCF MarginFCF / Revenue | — | 8.6% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | 9.62× |
| TTM Free Cash FlowTrailing 4 quarters | — | $29.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $16.3M | ||
| Q3 25 | — | $35.7M | ||
| Q2 25 | — | $-26.5M | ||
| Q1 25 | — | $7.8M | ||
| Q4 24 | — | $-3.9M | ||
| Q3 24 | — | $-23.0M | ||
| Q2 24 | — | $22.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $16.0M | ||
| Q3 25 | — | $35.3M | ||
| Q2 25 | — | $-28.9M | ||
| Q1 25 | — | $7.5M | ||
| Q4 24 | — | $-4.2M | ||
| Q3 24 | — | $-23.3M | ||
| Q2 24 | — | $21.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 8.6% | ||
| Q3 25 | — | 20.9% | ||
| Q2 25 | — | -18.7% | ||
| Q1 25 | — | 6.0% | ||
| Q4 24 | — | -2.8% | ||
| Q3 24 | — | -16.5% | ||
| Q2 24 | — | 17.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 1.6% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 9.62× | ||
| Q3 25 | — | 2.06× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FLX
Segment breakdown not available.
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
